UBS Group AG Grows Stake in Certara, Inc. $CERT

Posted by Brian Himes on May 12th, 2026

UBS Group AG boosted its position in shares of Certara, Inc. (NASDAQ:CERT – Free Report) by 50.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,489,603 shares of the company’s stock after acquiring an additional 837,648 shares during the quarter. UBS Group AG’s holdings in Certara were worth $21,933,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Wasatch Advisors LP grew its stake in shares of Certara by 45.7% during the 2nd quarter. Wasatch Advisors LP now owns 13,532,882 shares of the company’s stock valued at $158,335,000 after purchasing an additional 4,244,230 shares during the period. Deerfield Management Company L.P. boosted its holdings in shares of Certara by 71.7% in the third quarter. Deerfield Management Company L.P. now owns 6,739,537 shares of the company’s stock worth $82,357,000 after buying an additional 2,813,438 shares during the last quarter. Fort Washington Investment Advisors Inc. OH boosted its holdings in shares of Certara by 133.4% in the fourth quarter. Fort Washington Investment Advisors Inc. OH now owns 2,272,823 shares of the company’s stock worth $20,024,000 after buying an additional 1,299,109 shares during the last quarter. Ameriprise Financial Inc. grew its position in Certara by 27.1% during the second quarter. Ameriprise Financial Inc. now owns 5,460,630 shares of the company’s stock valued at $63,889,000 after buying an additional 1,165,064 shares during the period. Finally, Brown Brothers Harriman & Co. grew its position in Certara by 34.8% during the third quarter. Brown Brothers Harriman & Co. now owns 3,764,034 shares of the company’s stock valued at $45,996,000 after buying an additional 972,669 shares during the period. 73.96% of the stock is owned by hedge funds and other institutional investors.

Certara Stock Down 18.7%

Shares of CERT stock opened at $5.13 on Tuesday. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.05 and a quick ratio of 2.05. Certara, Inc. has a one year low of $4.99 and a one year high of $13.88. The company’s fifty day moving average price is $6.21 and its 200-day moving average price is $8.01. The company has a market capitalization of $786.53 million, a price-to-earnings ratio of -513.00 and a beta of 1.53.

Certara (NASDAQ:CERT – Get Free Report) last issued its quarterly earnings results on Monday, May 11th. The company reported $0.09 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.02). The business had revenue of $106.92 million during the quarter, compared to analysts’ expectations of $106.13 million. Certara had a positive return on equity of 4.20% and a negative net margin of 0.38%.The company’s quarterly revenue was up .8% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.14 EPS. Certara has set its FY 2026 guidance at 0.350-0.410 EPS. Sell-side analysts expect that Certara, Inc. will post 0.29 EPS for the current fiscal year.

Certara News Roundup

Here are the key news stories impacting Certara this week:

Neutral Sentiment: Certara said its AI investments are intended to support long-term growth, which could help the company’s platform and future revenue opportunities. Certara says AI investments will drive long-term growth – but traders are focused on one warning
Neutral Sentiment: The company reported quarterly revenue of $106.92 million, slightly ahead of expectations, showing modest top-line growth despite mixed overall results. Certara Reports First Quarter 2026 Financial Results
Negative Sentiment: Adjusted EPS of $0.09 missed the $0.11 consensus estimate, reinforcing concerns that earnings momentum is weaker than expected. Certara, Inc. (CERT) Q1 Earnings Miss Estimates
Negative Sentiment: Management cut FY 2026 guidance to EPS of $0.350-$0.410 and revenue of $395 million-$405 million, both below Wall Street forecasts, which appears to be the main reason the stock is falling. Certara (CERT) shares slide after weak full-year guidance overshadows revenue beat
Negative Sentiment: The earnings miss and weaker outlook helped push CERT to a new 52-week low, and the stock was even halted briefly during trading due to a LULD pause, highlighting elevated volatility. Certara (NASDAQ:CERT) Hits New 52-Week Low After Earnings Miss

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on CERT shares. Wall Street Zen cut shares of Certara from a “buy” rating to a “hold” rating in a research note on Sunday, February 15th. TD Cowen reaffirmed a “buy” rating on shares of Certara in a report on Thursday, February 26th. Craig Hallum downgraded Certara from a “buy” rating to a “hold” rating and set a $10.00 target price on the stock. in a research report on Friday, February 27th. KeyCorp cut their price target on Certara from $10.00 to $8.00 and set an “overweight” rating for the company in a report on Monday, April 13th. Finally, Leerink Partners restated an “outperform” rating and issued a $10.00 price target on shares of Certara in a research report on Thursday, February 26th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $10.44.

Read Our Latest Report on CERT

About Certara

(Free Report)

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.